The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.
FDA updates warning labels on gadolinium contrast
Sep 8, 2010
Latest in MRI
3D MRI technique helps plan treatment for pediatric heart conditions
February 12, 2026
Siemens Healthineers, Mayo Clinic expand collaboration
February 12, 2026
Philips introduces InkSpace Imaging’s Snuggle for pediatric MRI
February 12, 2026
Wellumio nabs $7.3M for portable MRI
February 11, 2026

















